As Jarcho and Keaney noted in their accompanying editorial, a main factor limiting potential long term effectiveness is the discontinuation rate of 42% overall, or 7% yearly. What are the primary reasons for patients to discontinue their lipid-lowering therapy, and what can be done to maintain adherence to treatment in the long-term? Do you think long-term adherence might be better if ezetimibe were used in combination with a statin that is generally better tolerated (i.e., has less potential for drug interactions and adverse side effects, such as myopathy) than simvastatin?
Easy one-click social registrationIs this safe?
We only receive the minimum information necessary to verify your account. We never get access to your friends/contacts or your profile, and we never post on your behalf. Your social account is used for logging in only.ORRegister via email
Send me updates on this Contest
In order to ensure a fair voting process and to make sure that no one votes more than once, we ask that you register either with a social networking account (easiest, only requires one click) or by registering with your email address (this will require you to click on a verification email that we will send you).
You only need to register once.